Genomic Health

Genomic Health was a biotechnology and molecular-diagnostics company focused on using tumor biology and genomic information to support cancer-treatment decisions. Founded in 2000 in Redwood City, California, the company emerged during a period when genetic research was beginning to move from academic laboratories into routine clinical decision-making. Its central proposition was that molecular characteristics of a tumor could provide more individualized information than conventional clinical and pathological measures alone. The company was founded by Randy Scott, who had previously founded and led Incyte. The founding concept was influenced by the diagnosis of cancer in a close friend and by the possibility that treatment could be tailored to the genome of an individual tumor. Genomic Health spent more than three years developing its first major commercial assay. That work resulted in Oncotype DX, a test initially designed to estimate the likelihood of breast-cancer recurrence and to help determine whether a patient was likely to benefit from chemotherapy. Oncotype DX became Genomic Health's defining product and brand. Rather than functioning as a general-purpose genetic test, it was positioned as a clinical decision-support tool for specific cancers. The breast Recurrence Score assay analyzed the activity of selected genes in tumor tissue and generated a score intended to complement established clinical information. This approach addressed a major challenge in oncology: identifying patients who could safely avoid the toxicity of chemotherapy while preserving treatment benefits for those at higher risk. Genomic Health subsequently broadened its portfolio beyond breast cancer. Its offerings included tests associated with colon cancer recurrence and prostate-cancer risk or treatment decisions. The company's business model centered on laboratory-developed molecular assays, clinical validation, physician adoption, payer coverage, and the integration of test results into treatment pathways. Its customers and stakeholders therefore included oncologists, surgeons, pathologists, hospitals, health systems, insurers, and patients. The company became publicly traded in 2005, listing on Nasdaq under the symbol GHDX. It also expanded its international presence, establishing international headquarters in Geneva and United Kingdom headquarters in London in 2011. In 2010, Genomic Health helped establish Invitae as a subsidiary intended to aggregate multiple genetic tests; Invitae was spun off in 2012. Genomic Health was acquired by Exact Sciences Corporation in 2019. The transaction combined Genomic Health's oncology testing portfolio, clinical evidence, and physician relationships with Exact Sciences' existing diagnostics business. Genomic Health no longer operates as an independent public company, but its most important product family continues within Exact Sciences' oncology diagnostics activities. Historically, the company is significant for helping establish genomic assays as commercially relevant tools in cancer treatment planning and for translating gene-expression research into routine clinical use.

Genomic Health was established in 2000 in Redwood City, California, by Randy Scott, a biotechnology executive who had previously founded and served as chief executive of Incyte. The company was created around the idea that the molecular profile of a cancer could provide clinically useful information for selecting treatment. This represented a shift from relying exclusively on tumor size, stage, histology, and other conventional measures toward incorporating gene-expression data into treatment planning. The company's first major development was Oncotype DX, a genomic assay for breast cancer. Development took more than three years and required substantial investment before the test could be offered commercially. The assay was designed to quantify the activity of a defined set of genes in tumor tissue and translate that information into a recurrence-risk score. The practical goal was not simply to classify a tumor genetically, but to help physicians and patients weigh the likely value of chemotherapy against its adverse effects. At the time, Genomic Health had to persuade clinicians, researchers, and other healthcare stakeholders that genomic testing could produce sufficiently reliable and actionable information for routine oncology care. Oncotype DX became the company's principal commercial and scientific platform. Genomic Health built its business around clinical validation, physician education, laboratory testing, and reimbursement. Its work contributed to the wider adoption of molecular diagnostics in oncology, particularly in situations where treatment decisions were uncertain under conventional risk assessment. The company later extended the Oncotype DX brand into additional disease areas, including colon and prostate cancer, thereby seeking to apply its genomic-decision-support model beyond early-stage breast cancer. Genomic Health became a public company in 2005. In July of that year it filed for an initial public offering of up to $75 million in common stock. It subsequently began trading on Nasdaq on September 29, 2005, under the symbol GHDX. The public listing gave the company access to public-market capital while increasing reporting and commercial expectations for a business whose value depended heavily on clinical evidence and adoption by the medical community. The company also pursued broader participation in the genetics-testing sector. In 2010 it established Invitae as a subsidiary with the aim of bringing together multiple genetic tests. Invitae was spun off in 2012 and later developed as a separate genetics company. Genomic Health meanwhile concentrated its identity and commercial resources on cancer testing. International expansion followed, including the establishment of international headquarters in Geneva and United Kingdom headquarters in London in 2011. In July 2019, Exact Sciences announced that it would purchase Genomic Health. The strategic rationale was to combine Exact Sciences' diagnostics activities with Genomic Health's established oncology-testing portfolio and clinical infrastructure. The transaction ended Genomic Health's existence as an independent public company and brought its products and capabilities into Exact Sciences. Genomic Health's historical importance rests primarily on the commercialization of genomic recurrence-risk testing and on its role in making molecular information a recognized component of individualized cancer-treatment decisions.

1. 2019Exact Sciences announces acquisition

   Exact Sciences announced its purchase of Genomic Health, bringing the company into a larger diagnostics business.

   Source
2. 2012Invitae is spun off

   Invitae was separated from Genomic Health as an independent company.

   Source
3. 2011International headquarters are established

   The company expanded its international structure with headquarters in Geneva and United Kingdom headquarters in London.

   Source
4. 2010Invitae is established as a subsidiary

   Genomic Health established Invitae to aggregate and provide multiple genetic tests.

   Source
5. 2005Initial public offering and Nasdaq listing

   Genomic Health filed for an initial public offering and began trading on Nasdaq under the symbol GHDX on September 29.

   Source
6. 2003Oncotype DX is developed

   After more than three years of development, Genomic Health produced its first major genomic assay, designed to estimate breast-cancer recurrence risk.

   Source
7. 2000Genomic Health is founded

   Randy Scott founded Genomic Health in Redwood City, California, with a focus on applying genomic research to cancer diagnosis and treatment decisions.

   Source

Precision oncology and molecular diagnostics designed to support individualized cancer-treatment decisions.

• Oncotype DX Breast Recurrence ScoreBreast-cancer genomic assay2003

  Genomic Health's best-known product was a gene-expression assay for breast-cancer tissue. It was designed to estimate the likelihood of recurrence and to provide information that could help clinicians assess whether chemotherapy was likely to add meaningful benefit. The test became the foundation of the Oncotype DX platform and the company's commercial identity in precision oncology.

• Oncotype DX Colon Recurrence ScoreColon-cancer genomic assay

  This test extended the Oncotype DX approach into colon cancer. It was intended to provide genomic information about recurrence risk that could complement conventional clinical and pathological factors when treatment plans were being considered.

• Oncotype DX ProstateProstate-cancer genomic assay

  The prostate offering applied Genomic Health's genomic-testing model to prostate cancer. Its purpose was to add tumor-biology information to treatment and risk assessment, helping clinicians evaluate disease characteristics beyond standard measures.

• 2019Acquisition by Exact SciencesM&A

  Exact Sciences wanted to broaden its medical-testing portfolio, while Genomic Health brought an established oncology-testing platform and clinical expertise.

  What changed. Exact Sciences announced the purchase of Genomic Health and subsequently combined the businesses.

  Aftermath. Genomic Health ceased to operate as an independent public company, while its oncology diagnostics became part of Exact Sciences.

  Source
• 2005Initial public offeringOther

  Genomic Health required public-market financing as it commercialized genomic oncology testing.

  What changed. The company filed to offer up to $75 million in common stock and subsequently listed on Nasdaq under GHDX.

  Aftermath. Genomic Health became a publicly traded diagnostics company.

  Proposed common-stock offering. $75 million (2005 IPO filing)

  Source
• 2003Commercial development of Oncotype DXProduct launch

  Genomic Health sought to turn gene-expression research into a clinically usable tool for breast-cancer treatment decisions.

  What changed. The company completed development of an assay intended to quantify recurrence risk from tumor genomic information.

  Aftermath. Oncotype DX became the company's flagship product and established its position in precision oncology diagnostics.

  Development investment. $30 million (More than three years of development through 2003)

  Source

• 2019Exact Sciences announces acquisition of Genomic Health

  Exact Sciences announced that it would acquire Genomic Health to broaden its portfolio of medical tests and combine two oncology-focused diagnostics businesses.

  M&A
  Source
• 2012Invitae is spun off from Genomic Health

  Invitae, a genetics-testing subsidiary established by Genomic Health, was separated from the company.

  M&AOther
  Source
• 2011Genomic Health expands international operations

  The company established international headquarters in Geneva and United Kingdom headquarters in London as it expanded outside the United States.

  Other
  Source
• 2005Genomic Health files for an initial public offering

  Genomic Health filed to offer up to $75 million of common stock as it prepared to become a publicly traded company.

  Other
  Source
• 2005Genomic Health begins trading on Nasdaq

  The company was listed on Nasdaq under the ticker GHDX, with an initial share price of $12.

  Other
  Source

1. Genomic Health